Nexeon acquires licence to 86 IoT patents and receives ISO 13485 certification

Nexeon MedSystems, a company that provides deep learning systems for implantable medical devices has licensed a portfolio of patents from Marathon Patent Group.

The portfolio of 86 patents originated from Siemens AG, protects innovations in the Internet-of-Things (IoT) space, which can be described as the interconnection via the internet of computing devices embedded in everyday objects, enabling them to send and receive data. This technology can be used in a variety of medical device applications, notably in hospitals, nursing facilities, or patients’ homes.

“The data gathered in these IoT systems can be utilised to help improve the programming for implantable devices,” said Nexeon chairman and CEO Will Rosellini. “An average patient with a chronic disease typically takes more than five different medications everyday, most of which need to be taken at different times of the day and have specific dietary recommendations to accompany the dosages.

This same patient is typically demonstrating symptoms associated with cognitive, psychiatric, and motor disorders as well. The promise of keeping the device in the right therapeutic range with data from the IoT is extraordinary.”

The portfolio’s subject matter is directed toward self-healing control networks for building automation systems in the hospital and the home. The patents are relevant to wireless mesh networks for use in the IoT and enable simple commissioning, application level security, simplified bridging, and end-to-end IP security.

There is a growing trend in electrophysiology toward remote home-monitoring of implantable cardioverter defibrillators (ICDs), cardiac resynchronisation therapy (CRT) devices, pacemakers, and implantable cardiac monitors (ICMs).

Will Rosellini

By enabling more automated device management and data integration, advanced devices could enable the quantified self. The company has engaged Battelle to define the data structures and cybersecurity protocols needed to provide the framework for deep learning.

“Siemens is one of the most innovative firms in the world,” Rosellini continued. “Integrating their network innovation with our patient-specific solutions will substantially reduce the burden of chronic disease. By addressing this unmet need, we will create tremendous value in the form of better, faster care with fewer in-office visits required, easier access to more accurate patient information, and decreased complications and undesired side effects due to more precise therapy and better monitoring.”

ISO 13485 cetification

Liege-based Nexeon Medsystems Belgium, SPRL has received certification from DEKRA CERTIFICATION B.V. that the company complies with the European requirements of ISO 13485 and EN ISO 13485 for a comprehensive quality management system for the design and manufacture of the company’s implantable neurostimulation system.

Company management has described this as a critical milestone on the path to launching its neuromodulation platform, both for its leading indication in deep brain stimulation (DBS) for Parkinson’s disease as well as follow-on products for other neurological diseases.

“Nexeon has an ongoing commitment to delivering the most advanced and highest quality neuromodulation devices for the treatment of neurologic diseases,” said Nexeon VP of Quality Dr. Stéphane Béfahy. He continued, “We are deliberately investing in our design and production processes in preparation for the commercial launch of our first product as well as the delivery of products for third-party device contracts that are currently in progress.”

Since 2013, the team at Nexeon Belgium has received both research grants and commercial contracts to advance the development and manufacture of its neuromodulation platform and related peripherals. The grants include a €3.4 million(US$ 3.72 million) funded consortium partnership in alignment with Minister Marcourt’s e-health initiative for the Walloon Region in Belgium.

The company’s most notable commercial contract is a multi-year agreement with Galvani Bioelectronics, a joint venture of Google/Verily and GlaxoSmithKline (GSK). After an exhaustive search, Galvani selected Nexeon’s platform to conduct its novel preclinical work. The contract is ongoing as Galvani exercised its option to enter the second phase last year.

Comment on this article below or via Twitter: @IoTNow_ OR @jcIoTnow

Recent Articles

What private blockchain means to telcos

Posted on: August 2, 2021

While the telecoms sector is yet to fully embrace blockchain technology, Jonas Lundqvist, CEO at Haidrun, says that the arrival of private blockchain may change that and unlock a massive potential for telecom service providers to create new businesses and revenue streams.

Read more

The Chinese market is expected to lead the development of V2X

Posted on: August 2, 2021

According to a new research report from the IoT analyst firm Berg Insight, there were about 0.7 million cars with V2X capabilities on the roads at the end of 2020. This number is expected to grow to 35.1 million by 2025. Communications between vehicles has been discussed for more than two decades, but with few

Read more